Press release
Anaplastic Thyroid Cancer Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight
"Anaplastic Thyroid Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anaplastic Thyroid Cancer Market.
The Anaplastic Thyroid Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Anaplastic Thyroid Cancer Pipeline Report: https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Anaplastic Thyroid Cancer treatment therapies with a considerable amount of success over the years.
• Anaplastic Thyroid Cancer companies working in the treatment market are AffyImmune Therapeutics, Faron Pharmaceuticals Ltd, Codiak BioSciences, Shanghai Henlius Biotech, Taizhou Hanzhong biomedical co. LTD, Merck & Co, Takeda Oncology, and others, are developing therapies for the Anaplastic Thyroid Cancer treatment
• Emerging Anaplastic Thyroid Cancer therapies in the different phases of clinical trials are- AIC100, FP-1305, CDK-002, HLX208, HX008, Pembrolizumab, Sapanisertib, and others are expected to have a significant impact on the Anaplastic Thyroid Cancer market in the coming years.
• In April 2025, Akiram Therapeutics announced the enrollment of the first patient in the Phase I clinical trial for its drug candidate 177Lu-AKIR001.
• In July 2024, AffyImmune announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its CAR T-cell product candidate, AIC100, for treating patients with recurrent anaplastic thyroid cancer (ATC), the most aggressive form of the disease.
• In May 2024, AffyImmune Therapeutics, a biotechnology company in the clinical stage focused on creating innovative, first-of-its-kind CAR T cell therapies, has released preliminary findings from a Phase 1 trial assessing the safety and effectiveness of AIC100. This therapy targets ICAM-1 and features an affinity-tuned LFA-1 binder, designed for patients with advanced thyroid cancer. Remarkably, one patient with anaplastic thyroid cancer (ATC), the most aggressive type of thyroid cancer, achieved a metabolic complete response (mCR).
Anaplastic Thyroid Cancer Overview
Anaplastic Thyroid Cancer is a rare and highly aggressive form of thyroid cancer. It develops from thyroid follicular cells but grows and spreads rapidly, often invading nearby tissues and metastasizing to other organs. ATC typically affects older adults and is associated with poor prognosis, with a median survival of only a few months after diagnosis. Symptoms may include a rapidly enlarging neck mass, difficulty swallowing, hoarseness, and breathing problems. Due to its aggressive nature, treatment usually involves a combination of surgery, radiation, and systemic therapies, though outcomes remain limited.
Get a Free Sample PDF Report to know more about Anaplastic Thyroid Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Anaplastic Thyroid Cancer Drugs Under Different Phases of Clinical Development Include:
• AIC100: AffyImmune Therapeutics
• FP-1305: Faron Pharmaceuticals Ltd
• CDK-002: Codiak BioSciences
• HLX208: Shanghai Henlius Biotech
• HX008: Taizhou Hanzhong biomedical co. LTD
• Pembrolizumab: Merck & Co
• Sapanisertib: Takeda Oncology
Anaplastic Thyroid Cancer Route of Administration
Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Anaplastic Thyroid Cancer Molecule Type
Anaplastic Thyroid Cancer Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Anaplastic Thyroid Cancer Pipeline Therapeutics Assessment
• Anaplastic Thyroid Cancer Assessment by Product Type
• Anaplastic Thyroid Cancer By Stage and Product Type
• Anaplastic Thyroid Cancer Assessment by Route of Administration
• Anaplastic Thyroid Cancer By Stage and Route of Administration
• Anaplastic Thyroid Cancer Assessment by Molecule Type
• Anaplastic Thyroid Cancer by Stage and Molecule Type
DelveInsight's Anaplastic Thyroid Cancer Report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Anaplastic Thyroid Cancer product details are provided in the report. Download the Anaplastic Thyroid Cancer pipeline report to learn more about the emerging Anaplastic Thyroid Cancer therapies at:
https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Anaplastic Thyroid Cancer Therapeutics Market include:
Key companies developing therapies for Anaplastic Thyroid Cancer are - Johnson and Johnson, Medtronic Plc, Merck KGaA, Novartis AG, Pfizer Inc., Akorn Inc., Amneal Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Viatris Inc., and others.
Anaplastic Thyroid Cancer Pipeline Analysis:
The Anaplastic Thyroid Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
• Anaplastic Thyroid Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Anaplastic Thyroid Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Anaplastic Thyroid Cancer Pipeline Market Drivers
• Rising prevalence of thyroid cancer, improving Healthcare Infrastructure, demand for New and Effective Drugs, increasing awareness about anaplastic thyroid cancer are some of the important factors that are fueling the Anaplastic Thyroid Cancer Market.
Anaplastic Thyroid Cancer Pipeline Market Barriers
• However, high cost of treatment, adverse effects associated with the chemotherapy and other factors are creating obstacles in the Anaplastic Thyroid Cancer Market growth.
Scope of Anaplastic Thyroid Cancer Pipeline Drug Insight
• Coverage: Global
• Key Anaplastic Thyroid Cancer Companies: AffyImmune Therapeutics, Faron Pharmaceuticals Ltd, Codiak BioSciences, Shanghai Henlius Biotech, Taizhou Hanzhong biomedical co. LTD, Merck & Co, Takeda Oncology, and others
• Key Anaplastic Thyroid Cancer Therapies: AIC100, FP-1305, CDK-002, HLX208, HX008, Pembrolizumab, Sapanisertib, and others
• Anaplastic Thyroid Cancer Therapeutic Assessment: Anaplastic Thyroid Cancer current marketed and Anaplastic Thyroid Cancer emerging therapies
• Anaplastic Thyroid Cancer Market Dynamics: Anaplastic Thyroid Cancer market drivers and Anaplastic Thyroid Cancer market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anaplastic Thyroid Cancer Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight here
News-ID: 4204251 • Views: …
More Releases from DelveInsight Business Research
Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2025: MOA and ROA Insights, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Relapsed/Refractory Acute Myeloid Leukemia pipeline constitutes 50+ key companies continuously working towards developing 75+ Relapsed/Refractory Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Primary Sclerosing Cholangitis Pipeline 2025: FDA Updates, Therapy Innovations, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Sclerosing Cholangitis pipeline constitutes 14+ key companies continuously working towards developing 14+ Primary Sclerosing Cholangitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Primary Sclerosing Cholangitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Sclerosing Cholangitis…
Polymyositis Market on Track for Major Expansion by 2034, According to DelveInsi …
DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Polymyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyositis Market Forecast
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Polymyositis…
DelveInsight Enables Strategic Partner Identification for Oncology Biopharma Adv …
DelveInsight, a leading life science market research and strategic consulting firm, today announced the successful completion of a comprehensive Partner Identification and Assessment Program for a US-based mid-sized pharmaceutical company developing a novel clinical-stage oncology asset targeting Head and Neck Cancer. The engagement focused on identifying co-development and commercialization partners across the United States and European markets to accelerate late-stage clinical progress and market entry.
Discover how your oncology asset can…
More Releases for Anaplastic
Anaplastic Astrocytoma Market Outlook, Epidemiology, Landscape and Growth Trajec …
Anaplastic astrocytoma (AA) is a rare, malignant brain tumor classified as World Health Organization (WHO) Grade III glioma, characterized by its aggressive nature and poor prognosis. While not as common as glioblastoma, anaplastic astrocytoma represents a significant challenge due to its high recurrence rates, limited treatment options, and resistance to conventional therapies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70897
Over the past decade, the treatment landscape has slowly evolved…
Anaplastic Large Cell Lymphoma Drugs Market: An In-Depth Analysis
The global Anaplastic Large Cell Lymphoma Drugs market was valued approximately USD 10.5 billion in 2022 and is projected to reach around USD 17.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5% during the forecast period.
Anaplastic Large Cell Lymphoma Drugs Market Overview
Anaplastic Large Cell Lymphoma is a rare type of non-Hodgkin lymphoma characterized by the proliferation of large lymphoid cells. The market for ALCL…
Anaplastic Astrocytoma Market Development, Trends, Segmentations Analysis
Anaplastic astrocytoma is a very rare type of malignant brain tumor affecting human at all ages. As this tumor develops from astrocytes, the star-shaped brain cells it is termed as astrocytoma. The astrocytes along with other cells protect nerve cells in the brain and spinal cord by surrounding them. All these protective cells are collectively termed as glial cells. World Health Organization (WHO) graded these tumors on a scale from…
Anaplastic Astrocytoma - Pipeline Review, H2 2017 - Pharmaceutical Report
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among…
Anaplastic Oligoastrocytoma Market Snapshot by 2024 – Persistence Market Resea …
Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear…
Latest Report Details Of Global Anaplastic Thyroid Cancer Market
Marketresearchreports.biz has added a new research report on the "Anaplastic Thyroid Cancer-Pipeline Insights, 2017" to its collection.
DelveInsights, Anaplastic Thyroid Cancer- Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Thyroid Cancer. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical…
